pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Doxorubicin Hydrochloride
drug
save

Farmiblastina

Marketedupdated 6mo ago
by $PFE PFIZER INC
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval60 co-mentions · 30 sources
  • drugDoxil59 co-mentions · 30 sources
  • drugDOXIL (LIPOSOMAL)59 co-mentions · 30 sources
  • drugDoxorubicin Teva31 co-mentions · 31 sources
  • drugdoxorubicin31 co-mentions · 31 sources
  • drugdoxorubicin hydrochloride30 co-mentions · 30 sources
  • companyCity of Hope1 co-mentions · 1 sources
  • drugCHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone]1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Farmiblastina

  • phase2Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphomasuspendedn=24
  • phase3A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphomaactive not recruitingn=733
  • phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).recruitingn=605
  • phase2IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Canceractive not recruitingn=168
  • phase3A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)recruitingn=646
  • phase2Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphomarecruitingn=257
  • phase3A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)recruitingn=2,400
  • phase3A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancerrecruitingn=480

News(6)

  • ‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrence
    A standard chemotherapy drug loaded in nanoparticles has been able to penetrate the blood-brain barrier when administered shortly after resection of the tumor, new research has suggested.
    fiercebiotech · 3mo ago
  • Five Under 5: Top Oncology Videos for the Week of 5/3
    The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
    onclive · 6mo ago
  • Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
    Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.
    onclive · 6mo ago
  • Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
    Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.
    onclive · 6mo ago
  • ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
    Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
    onclive · 6mo ago
  • Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
    Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.
    onclive · 6mo ago
brand
Doxorubicin Hydrochloride
generic
doxorubicin
indication
Acute Lymphoblastic Lymphoma
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?